Robert Michael Dudley's most recent trade in TransCode Therapeutics Inc was a trade of 12,000 Common Stock done at an average price of $2.7 . Disclosure was reported to the exchange on June 20, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.65 per share. | 20 Jun 2023 | 12,000 | 82,262 | - | 2.7 | 31,818 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 20 Jun 2023 | 6,607 | 70,262 | - | 2.5 | 16,847 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.76 per share. | 09 Jun 2023 | 19,000 | 912,114 | - | 2.8 | 52,440 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 14 Sep 2022 | 20,000 | 893,114 | - | 1.2 | 23,000 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.84 per share. | 27 May 2022 | 28,000 | 871,114 | - | 1.8 | 51,643 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.87 per share. | 27 May 2022 | 2,000 | 873,114 | - | 1.9 | 3,740 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) |